Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06029439 · ClinicalTrials.gov registry record · Phase 3

Study to Assess the Safety and Effectiveness of NMRA-335140-501

A Phase 3 study of Major Depressive Disorder, sponsored by Neumora Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
1,000
Enrollment target
20
Study locations

NCT06029439: Recruiting Phase 3 study of Major Depressive Disorder, sponsored by Neumora Therapeutics.

NCT06029439 is a Phase 3 study of Major Depressive Disorder that is actively recruiting participants, run by Neumora Therapeutics. The registered enrollment target is 1,000 participants, above the 373-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (168% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06029439, a Phase 3 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Neumora Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.

Primary Outcome

An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, ECGs, Vital Signs, Physical and Ophthalmological examina

Conditions Studied

Major Depressive Disorder

Interventions

  • DRUG NMRA-335140

Study Locations (20)

California

  • Neumora Investigator site - Bellflower
  • Neumora Investigator Site - Cerritos
  • Neumora Investigator Site - Encino
  • Neumora Investigator Site - Garden Grove
  • Neumora Investigator Site - Glendale
  • Neumora Investigator Site - Imperial
  • Neumora Investigator Site - Irvine
  • Neumora Investigator Site - Lafayette
  • Neumora Investigator Site #1 - Long Beach
  • Neumora Investigator site - Long Beach
  • Neumora Investigator Site - Los Angeles
  • Neumora Investigator Site - Newport Beach
  • Neumora Investigator Site - Oceanside
  • Neumora Investigator Site #1 - Orange

Arkansas

  • Neumora Investigator Site - Bentonville
  • Neumora Investigator Site #1 - Little Rock
  • Neumora Investigator site - Little Rock
  • Neumora Investigator Site - Rogers

Alabama

  • Neumora Investigator site - Huntsville

Arizona

  • Neumora Investigator Site - Phoenix

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-11-10
Est. Completion 2027-06
Phase Phase 3
Neumora Therapeutics

7 total trials

What NCT06029439 shows while recruiting

NCT06029439 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 373-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (168% higher).

The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which NMRA-335140 is the first listed.

NCT06029439 names 20 study sites across 4 states, led by California, Arkansas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06029439 about?

NCT06029439 is a clinical study titled "Study to Assess the Safety and Effectiveness of NMRA-335140-501". This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD...

What is the current status of trial NCT06029439?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2023-11-10. Estimated completion is 2027-06.

What conditions does trial NCT06029439 study?

This clinical trial studies the following conditions: Major Depressive Disorder.

What interventions are being tested in trial NCT06029439?

The interventions under investigation include: NMRA-335140 (DRUG).

Who is sponsoring clinical trial NCT06029439?

This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06029439 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06029439's enrollment target sits among peer trials

1,000 7th of 282 higher than 274 of 282 other Major Depressive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06029439

Source: ClinicalTrials.gov NCT06029439, the US trial registry maintained by the National Library of Medicine. NCT06029439 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.